II. Indications

  1. Atrial Fibrillation with hemodynamic instability
  2. Atrial Fibrillation >48 hours on Anticoagulation for >6 weeks (or cleared of atrial thrombus by TEE)
  3. Atrial Fibrillation <48 hours and no significant left atrial enlargement
    1. See precautions in Atrial Fibrillation Cardioversion
      1. Thromboembolism risk still exists despite short duration of Atrial Fibrillation
    2. Consider Echocardiogram prior to cardioversion
    3. Left atrium >4.5 cm poorly maintains sinus rhythm

III. Contraindications

IV. Efficacy

  1. Conversion Rate: 86-94% (contrast 51% efficacy of chemical cardioversion)
    1. Higher success rates in Atrial Flutter than with Atrial Fibrillation

V. Dosing

  1. Dose adjustments
    1. Adjust dose if on Digoxin (see below)
    2. Higher dose (200 Joules) needed in Atrial Fibrillation, whereas lower doses are effective in Atrial Flutter
  2. Monophasic dose
    1. Synchronized: 200 joules (up to 360 joules)
    2. Starting at monophasic 200 joules minimizes cummulative shock exposure
      1. Justification: 100 J dose in Atrial Fibrillation has only 50% success rate (requiring second shock)
  3. Biphasic dose (preferred)
    1. Synchronized: 150 joules (up to 200 joules)
  4. Consider Antiarrhythmic pre-treatment prior to cardioversion in stable patients (controversial)
    1. Based on anecdotal experience, may improve electrical cardioversion success rate
    2. Option 1: Procainamide
      1. Procainamide 1 gram IV over 1 hour, then Synchronized Cardioversion if needed
      2. See Ottawa Aggressive Protocol in Atrial Fibrillation Cardioversion
    3. Option 2: Amiodarone
      1. Amiodarone 150 mg IV, then Synchronized Cardioversion if needed

VI. Precautions: Digoxin

  1. Do not use electrical cardioversion in Digoxin Toxicity (risk of malignant ventricular arrhythmia)
  2. Modified electrical cardioversion dosing in patients on Digoxin
    1. Start at 10-20 Joules biphasic
    2. Increase in 10-20 Joule increments until cardioversion

VII. Protocol

  1. Informed Consent
    1. See Atrial Fibrillation Cardioversion for risks
  2. Conscious Sedation
    1. See Synchronized Cardioversion for protocol
  3. Unfractionated Heparin or Low Molecular Weight Heparin indications
    1. Atrial Fibrillation of unknown duration or >48 hours (emergent, unstable cases requiring immediate cardioversion) or
    2. High risk of Cerebrovascular Accident (e.g. prior TIA or CVA, Rheumatic Heart Disease, Mechanical Heart Valve)

VIII. Management: Post-cardioversion

  1. See Atrial Fibrillation Acute Management
    1. Describes overall approach and disposition planning (including safe for discharge indications)
  2. Atrial Fibrillation Anticoagulation
    1. Describes indications for Anticoagulation and agents (Warfarin, Dabigatran, Oral Xa Inhibitors)
    2. Expert opinion typically recommends Anticoagulation for 3 weeks following cardioversion due to myocardial stunning
  3. See Atrial Fibrillation Rate Control
    1. Discharge patient on Metoprolol Tartrate (25 mg bid) or Metoprolol Succinate (25-50 mg daily) in most cases

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window